A 57-year-old man presented to our Department in 1997 when he was hospitalized for progressively worsening exertional dyspnea (modified medical research councilmMRC -scale grade 1) and productive cough, which he had had since 1990. The patient was a former smoker (16.5 pack-years), and at the time of first visit had been working for 20 years as a welder in a metalworking company. He had no further co-morbidities. Post bronchodilator (BD) spirometry showed a forced expiratory volume in the first second (FEV 1 ) of 2.25 L (56% of predicted), FEV 1 /FVC (forced vital capacity) of 52%, residual volume (RV) was 2.67 L (129%), oxygen saturation level of hemoglobin (SatHbO 2 ) was 96% and chest X-ray showed mild emphysema. A diagnosis was 
made of "chronic obstructive pulmonary disease (COPD) in subject professionally exposed to welding fumes" and inhalation therapy with budesonide 1.6 mg plus salmeterol 0.2 mg per day was prescribed, in addition to salbutamol 200 μg when needed.
In a follow-up visit (March 2000) , during a COPD exacerbation episode, the patient presented with a worsened clinical and functional profile, with exacerbation of dyspnea at rest and on exertion (mMRC scale grade 2) and with copious yellowish sputum. Post BD spirometry showed: FEV 1 ) 69.1 mmHg and partial pressure of oxygen in arterial blood (PaO 2 ) 50 mmHg. The 6-minute walking test (6MWT) was normal (walked 450 m, no desaturation after exercise). Chest computerized tomography (CT) scan without contrast medium showed signs of bullous emphysema at the level of the right lower lung lobe. The patient was therefore prescribed with inhalation therapy with fluticasone 2 mg and salmeterol 0.2 mg daily, tiotropium bromide 18 μg/day and salbutamol 200 μg when needed.
Between 2008 and 2011, the patient has been seen in our Department approximately every six months, reporting a progressive de- terioration of morning sputum and dyspnea on exertion (mMRC grade 2). COPD exacerbations requiring steroid therapy and oral antibiotics became more frequent (on average 3 per year). Arterial blood gas analysis showed resting hypoxemia (mean value of 76.5 mmHg) and hypercapnia (mean value of 45.6 mmHg). In November 2011, during a check-up visit, the patient complained about a marked exertional dyspnea (mMRC scale grade 3) and had recently recovered from a moderate COPD exacerbation. The functional profile (table 1 and figure 1 , before treatment data) was unchanged, as well as the radiological one (by means of a CT scan without contrast medium performed in January 2012). SatHbO 2 was 94.7%, pH 7.382, PaO 2 77.3 and PaCO 2 47.2. The 6MWT showed desaturation after exercise (from 95% to 93%) after walking 420 m. Therapy was unchanged.
The 31 st of January 2012 (treatment start) the patient was checked again (table 1 and figure 1 ) and, meeting the eligibility criteria for roflumilast therapy (as determined by Italian Drug Agency), he was prescribed this medication (500 μg/day). After 10 days of treatment the patient complained about profuse diarrhea for three days, therefore it was agreed to suspend the drug for 10 days and, in case of remission of diarrhea, to resume therapy. It must however be noted that, in the same days, the patient had taken a short course of oral amoxicillin for dental treatment.
The patient followed directions and restarted therapy with roflumilast, without subsequently reporting of any specific side effects or weight loss. Since then and until December 2012 (after 12 months of roflumilast treatment) he has not had any COPD exacerbations nor had he to take steroid therapy or oral antibiotics. Quality of life improved as evidenced by the COPD assessment test (CAT -from 27 prior to treatment with roflumilast to 10, after 12 months of treatment, figure 1A ), reducing dyspnea (mMRC scale grade 0-1) and productive cough. Lung function tests highlighted an increase of inspiratory capacity (IC) after bronchodilator, with response already after 3 months of therapy (15% increase) and further increase at the last control (+22%) (figure 1B) . At the same time, a decrease in RV after bronchodilator was noted, made more apparent in the last control (15% reduction) ( figure 1C) . The diffusion capacity of lung gas, although not particularly compromised during all the examined years, presented a progressive increase, reaching +47%. at the last control (after 12 months of treatment, table 1). In December 2012, the 6WMT was normal (walked for 490 m with no desaturation after exercise).
Discussion
The clinical case presented here describes the history of a patient with COPD stage D according to Guidelines GOLD 2013 [1] , in a subject professionally exposed to welding fumes. The course of the disease has been long and characterized by a progressive deterioration. The therapeutic option of adding roflumilast (500 μg/day) to the triple combination therapy, in line with the recommendations of the "Global Initiative for Chronic Obstructive Lung Disease" (GOLD) Guidelines [1, 2] , has been successful. It allowed a rapid clinical and functional improvement of the patient, and a good therapeutic control of the disease.
Efficacy of roflumilast treatment was further evidenced by the dramatic reduction of exacerbations and a marked improvement of respiratory symptoms, also evidenced by the improvement in CAT test scores. This score is particularly meaningful since it allows us to compare it to those reported in a recent meta-analysis [3] , in which roflumilast led to an improvement in respiratory symptoms and quality of life (analyzed by the St George's Respiratory Questionnaire), al-though was not found to be statistically significant.
Roflumilast therapy also led to an improved tolerance to exercise, as evidenced by the positive outcomes of the SatHbO 2 test, by the distance walked during the 6MWT and by the dyspnea levels after exercise (mMRC scale). This is in line with what has been previously documented by O'Donnell et al. [4] who showed an improvement in oxygen saturation and TDI (Transition Dyspnea Index) during cycling exercise in COPD patients treated with roflumilast compared to those treated with placebo. The same authors did not document any particular change in hyperinsufflation in static conditions (as well as during exercise) in patients treated with roflumilast. Our patient, instead, did experience a progressive reduction of the RV and an increase in IC after bronchodilator test.
In contrast to what has been reported by other authors [3, 5, 6] , in our patient no improvement in FEV 1 after bronchodilator test has been observed with roflumilast. On the other hand, a significant increase in lung gas diffusion capacity has been documented, which suggests a decreased ventilation-perfusion heterogeneity, although the mechanism of these changes is still unclear.
Treatment with roflumilast was well tolerated and safe, apart from the onset of diarrhea, which was documented in the course of concomitant antibiotic therapy, as already shown in other studies [3, 7] . The patient agreed to temporarily suspend roflumilast and then resume it and this regimen has proven to be efficient and may be suggested in common clinical practice. 
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